Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

L Gauthier, A Virone-Oddos, J Beninga, B Rossi… - Nature …, 2023 - nature.com
CD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid
leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting …

Systematic review of the burden and treatment patterns of adult and adolescent acute lymphoblastic leukemia in India: comprehending the challenges in an emerging …

VS Radhakrishnan, N Agrawal, B Bagal… - … Lymphoma Myeloma and …, 2021 - Elsevier
Background In the present systematic literature review, we sought to describe the burden
and treatment practices of adult acute lymphoblastic leukemia (ALL) in India, which reflect …

[HTML][HTML] Immunophenotypic characteristics of T lineage acute lymphoblastic leukemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon

R Gupta, N Garg, M Kotru, D Kumar… - American Journal of …, 2022 - ncbi.nlm.nih.gov
Introduction: T ALL may show variable morphological features and immunophenotypic
analysis for characterisation of immature nature of these cells is needed to establish a …

[PDF][PDF] Characterization of immunophenotypic aberrancies with respect to common fusion transcripts in B-cell precursor acute lymphoblastic leukemia: a report of 986 …

DG Gupta, N Varma, S Naseem… - Turkish Journal of …, 2022 - jag.journalagent.com
Objective: Based on the immunophenotype, acute lymphoblastic leukemia (ALL) can be
categorized into B-cell or T-cell lineages. B-cell precursor ALL (BCP-ALL) cases show …

CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry

AM Eckel, S Cherian, V Miller… - Cytometry Part B: Clinical …, 2020 - Wiley Online Library
Detection of minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML)
is important for guiding patient‐specific clinical management. Natural killer (NK) cells can …

CD146 molecule expression in B cells acute lymphoblastic leukemia (B-ALLs): a flow-cytometric marker for an accurate diagnostic workup

A Laganà, M Totaro, ML Bisegna, L Elia… - … of Hematology and …, 2024 - pmc.ncbi.nlm.nih.gov
Background B-lineage acute lymphoblastic leukemias (B-ALL) harboring the t (9; 22)(q34;
q11)/BCR:: ABL1 rearrangement represent a category with previously dismal prognosis …

[HTML][HTML] CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis

N Garg, R Gupta, M Kotru - Asian Pacific Journal of Cancer …, 2021 - ncbi.nlm.nih.gov
Background: CD34 antigen is expressed by early hematopoietic progenitor cells and acute
leukemia cells. Its expression is associated with good prognosis in acute myeloid leukemia …

[HTML][HTML] Immunophenotypic characterization of acute leukemias in Bahia, Brazil

MM Santos, AS Santos, HHM Santos, LS Santos… - Einstein (São …, 2023 - SciELO Brasil
Objective To characterize the immunophenotypic profile of acute leukemias in the
population of the state of Bahia, Brazil. Methods This is a descriptive, retrospective study …